A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
open access
Keywords
Clinical trial
Lot consistency
Immunogenicity and safety
Streptococcus pneumoniae
20-valent pneumococcal conjugate vaccine
Abbreviations
AE
adverse event
CRM197
cross-reactive material 197
GMFR
geometric mean fold rise
GMR
geometric mean ratio
GMT
geometric mean titer
IPD
invasive pneumococcal disease
LLOQ
lower limit of quantitation
NDCMC
newly diagnosed chronic medical condition
OPA
opsonophagocytic activity
PCV
pneumococcal conjugate vaccine
PCV7
7-valent pneumococcal conjugate vaccine
PCV13
13-valent pneumococcal conjugate vaccine
PCV20
20-valent pneumococcal conjugate vaccine
PPSV23
23-valent pneumococcal polysaccharide vaccine
SAE
serious adverse event
Cited by (0)
© 2021 Elsevier Ltd. All rights reserved.